Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("CIPROFIBRATE")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Language

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 199

  • Page / 8
Export

Selection :

  • and

CIPROFIBRATE IN THE THERAPY OF TYPE II HYPERCHOLESTEROLEMIA A DOUBLE-BLIND TRIALILLINGWORTH DR; OLSEN GD; COOK SF et al.1982; ATHEROSCLEROSIS; ISSN 0021-9150; NLD; DA. 1982; VOL. 44; NO 2; PP. 211-221; BIBL. 35 REF.Article

Separation of fibrate-type antihyperlipidemic drugs by capillary electrophoresis and their quantitation in pharmaceuticalsKOMSTA, Lukasz; MISZTAL, Genowefa; MAJCHRZAK, Ewa et al.Journal of pharmaceutical and biomedical analysis. 2006, Vol 41, Num 2, pp 408-414, issn 0731-7085, 7 p.Article

DOSE-RESPONSE STUDY OF THE EFFECT OF CIPROFIBRATE ON SERUM LIPOPROTEIN CONCENTRATIONS IN HYPERLIPOPROTEINAEMIAOLSSON AG; ORO L.1982; ATHEROSCLEROSIS; ISSN 0021-9150; NLD; DA. 1982; VOL. 42; NO 2-3; PP. 229-243; BIBL. 12 REF.Article

ZUM METABOLISMUS VON 2-(4-(2,2-DICHLORCYCLOPROPYL) PHENOXY)-2-METHYL-PROPIONSAEURE (CIPROFIBRAT) = METABOLISME DU 2-(4-(2,2 DICHLOROCYCLOPROPYL) PHENOXY)-2 METHYL PROPIONIQUE ACIDE (CIPROFIBRATE)BEYER KH; STADTER H.1982; ARCHIV DER PHARMACIE (WEINHEIM); ISSN 0365-6233; DEU; DA. 1982; VOL. 315; NO 12; PP. 1049-1051Article

BLOOD LEVELS, TISSUE DISTRIBUTION AND THE DURATION OF ACTION IN RATS OF CIPROFIBRATE, A NEW HYPOLIPIDEMIC AGENTEDELSON J; BENZIGER DP; ARNOLD A et al.1979; ATHEROSCLEROSIS; NLD; DA. 1979; VOL. 33; NO 3; PP. 351-357; BIBL. 8 REF.Article

Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatographyMASNATTA, L. D; CUNIBERTI, L. A; REY, R. H et al.Journal of chromatography. Biomedical applications. 1996, Vol 687, Num 2, pp 437-442, issn 0378-4347Article

Effects of ciprofibrate on testicular and adrenal steroidogenic enzymes in the ratHIERLIHY, Andrée M; COOKE, Gerard M; CURRAN, Ivan H. A et al.Reproductive toxicology (Elmsford, NY). 2006, Vol 22, Num 1, pp 37-43, issn 0890-6238, 7 p.Article

Role of the p50 subunit of NF-κB in vitamin E-induced changes in mice treated with the peroxisome proliferator, ciprofibrateCALFEE-MASON, Karen G; LEE, Eun Y; SPEAR, Brett T et al.Food and chemical toxicology. 2008, Vol 46, Num 6, pp 2062-2073, issn 0278-6915, 12 p.Article

Ciprofibrate quantification in human plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry for pharmacokinetic studiesMENDES, Fabiana D; LU SHI CHEN; BORGES, André et al.Journal of chromatography. B. 2011, Vol 879, Num 24, pp 2361-2368, issn 1570-0232, 8 p.Article

DETERMINATION OF CIPROFIBRATE IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHYPARK GB; BIDDLECOME CE; KOBLANTZ C et al.1982; J. CHROMATOGR.; ISSN 0021-9673; NLD; DA. 1982; VOL. 227; NO 2; PP. 534-539; BIBL. 6 REF.Article

Konjugationsreaktionen von Ciprofibrat bei Menschen und Versuchstieren = Conjugation reactions of ciprofibrate in humans and laboratory animalsOELSCHLÄGER, Herbert; MÜLLER, Dieter; HELLWICH, Karl-Heinz et al.Arzneimittel-Forschung. 2003, Vol 53, Num 4, pp 247-253, issn 0004-4172, 7 p.Article

Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and BROUFFY, J; CHANU, B; BAKIR, R et al.Atherosclerosis. 1985, Vol 54, Num 3, pp 273-281, issn 0021-9150Article

Ciprofibrate increases paraoxonase activity in patients with metabolic syndromePARAGH, György; SERES, Ildiko; HARANGI, Mariann et al.British journal of clinical pharmacology. 2006, Vol 61, Num 6, pp 694-701, issn 0306-5251, 8 p.Article

Effects of vitamin E on the NF-κB pathway in rats treated with the peroxisome proliferator, ciprofibrateCALFEE-MASON, Karen G; SPEAR, Brett T; GLAUERT, Howard P et al.Toxicology and applied pharmacology. 2004, Vol 199, Num 1, pp 1-9, issn 0041-008X, 9 p.Article

METABOLIC EFFECTS OF A NEW HYPOLIPIDEMIC AGENT, CIPROFIBRATEARNOLD A; MCAULIFF JP; BEYLER AL et al.1979; J. PHARM. SCI.; USA; DA. 1979; VOL. 68; NO 12; PP. 1557-1558; BIBL. 14 REF.Article

Differential effects of ciprofibrate on renal and hepatic cytochrome P450 2E1 expressionZANGAR, R. C; WOODCROFT, K. J; NOVAK, R. F et al.Toxicology and applied pharmacology. 1996, Vol 141, Num 1, pp 110-116, issn 0041-008XArticle

The levels of soluble adhesion molecules in diabetic and nondiabetic patients with combined hyperlipoproteinemia and the effect of ciprofibrate therapyOKAPCOVA, J; GABOR, D.Angiology. 2004, Vol 55, Num 6, pp 629-639, issn 0003-3197, 11 p.Article

Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias : An open-label, multicenter studyAGUILAR-SALINAS, Carlos Alberto; FANGHÄNEL-SALMON, Guillermo; MEZA, Edilberto et al.Metabolism, clinical and experimental. 2001, Vol 50, Num 6, pp 729-733, issn 0026-0495Article

Effets des proliférateurs de peroxysomes sur la régulation du cholestérol et de son métabolisme dans des modèles cellulaires d'origine hépatique = Effect of peroxisome proliferators on regulation of cholesterol and its metabolism in hepatic cellular modelsDuclos, Sandrine; Bournot, Paulette.1997, 149 p.Thesis

Effet d'un hypolipemiant sur l'expression de deux enzymes de la béta-oxydation peroxysomale des acides gras. 1- Acyl-CoA oxydase: analyse transcriptionnelle chez le rat. 2- Enzyme bifonctionnelle: caractérisation des ADNc et étude de leur expression chez le cochon d'Inde = Effect of an hypolipemic agent on the expression of two enzymes of the peroxisoma beta-oxidation. 1- Acyl-CoA oxidase: transcription al analysis in the rat. 2- Bifunctional Enzyme: characterization of cDNAs and study of their expression in the guinea pigCaira, Françoise; Latruffe, N.1996, 147 p.Thesis

Ciprofibrate, Clofibric Acid and Respective Glycinate Derivatives : Effects of a four-week treatment on male lean and obese Zucker ratsLUPP, Amelie; KARGE, Elke; DEUFEL, Thomas et al.Arzneimittel-Forschung. 2008, Vol 58, Num 5, pp 225-241, issn 0004-4172, 17 p.Article

Hépatite cholestatique aiguë lors de la prise de ciprofibrate = Ciprofibrate: induced acute cholestatic hepatitisPFLUMIO, F; ANDRES, E; UBRICH, M et al.Annales d'endocrinologie. 2003, Vol 64, Num 3, pp 232-233, issn 0003-4266, 2 p.Article

Effect of ciprofibrate on C-reactive protein and fibrinogen levelsRIZOS, Evagelos; KOSTOULA, Angeliki; ELISAF, Moses et al.Angiology. 2002, Vol 53, Num 3, pp 273-277, issn 0003-3197Article

Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrateTURAY, J; GRNIAKOVA, V; VALKA, J et al.Drugs under experimental and clinical research. 2000, Vol 26, Num 3, pp 83-88, issn 0378-6501Article

Zur Pharmakokinetik von Lipidsenkern. IV: Biotransformation des Lipidsenkers Ciprofibrat 2-(4-(2,2-Dichlorcyclopropyl) phenoxy)-2-methylpropionsäure = Pharmacocinétique d'Agent hypolipidémique, IV: métabolisme de l'agent hypolipidémique Ciprofibrate2-(4-(2,2-Dichlorocyclopropyl)-phenoxy)-2 methyl propanoic acid = Pharmacokinetics of hypolipidemic agents, IV: metabolism of the hypolipidemic Agent ciprofibrat 2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-2-methylpropanoic acidOELSCHLÄGER, H; ROTHLEY, D; SCHMIDT, W et al.Archiv der Pharmazie (Weinheim). 1988, Vol 321, Num 6, pp 367-370, issn 0365-6233Article

  • Page / 8